Euphyllin retard N

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Euphyllin retard N

Property Description
Active ingredient Theophylline
Form Sustained-Release Tablet (Retard Tablet)
Pharmacological class Xanthine Derivative / Bronchodilator
Common use Long-term breathing support
Origin Synthetic

What is Euphyllin retard N and Its Active Ingredient?

Euphyllin retard N is a brand name for an oral medicine that contains the single active ingredient Theophylline, which is chemically classified as a Xanthine derivative. This compound is a synthetic drug widely recognized for its function as a bronchodilator, helping to widen the air passages in the lungs.

Theophylline is an established drug that has been clinically recognized for decades to provide symptomatic relief in chronic respiratory disorders. The product is typically sold as a prescription-only (Rx) medication used for long-term management.


How is Euphyllin retard N Classified?

The medicine is supplied in the sustained-release (retard) tablet dosage form for oral administration. The specialized "retard" formulation is its key feature, designed to control the rate at which Theophylline is released into the body.

This design ensures that the active substance is released slowly and steadily over many hours, which helps maintain a continuous, stable concentration in the body. This modified-release approach is designed to provide consistent support for breathing.


What is the General Purpose of This Medicine?

The general purpose of Euphyllin retard N is to provide reliable, long-term maintenance support for respiratory stability. It achieves this by acting as a smooth muscle relaxant on the involuntary muscles that surround the bronchial tubes.

This action, known as bronchodilation, supports stable and consistent airflow. A typical use scenario involves a patient taking the tablet to help prevent daily and nightly episodes of shortness of breath by keeping the airways consistently open.

Regulatory References

  1. Guideline on the pharmacokinetic and clinical evaluation of modified-release dosage forms
Advertisements

What side effects are possible with Euphyllin retard N?

Possible side effects and safety information

Euphyllin retard N, which contains the active ingredient Theophylline, has a documented safety profile that is highly dependent on the drug's concentration in the bloodstream. The risk of adverse reactions, including serious events, is minimized when blood levels are maintained within the 10-15 mu g/mL therapeutic range, as exceeding 20 mu g/mL significantly increases the frequency and severity of side effects.

Adverse reactions are officially categorized across several System-Organ Classes, primarily affecting the Gastrointestinal system (nausea, vomiting, diarrhea), the Nervous System (headache, tremors, restlessness, insomnia), and the Cardiovascular system (tachycardia, abnormal heart rhythm). Serious adverse reactions documented in regulatory labeling include Seizure and Severe Cardiac Arrhythmias.

Special Population Safety: The official label notes that the drug's clearance is significantly reduced in certain populations, notably older adults and patients with hepatic impairment or Congestive Heart Failure. This necessitates consideration when determining a patient's appropriate therapeutic management. Furthermore, theophylline is officially classified as a Narrow Therapeutic Index (NTI) drug, underscoring the narrow margin between effective and potentially toxic concentrations. The presence of a high fever is also documented as a factor that can reduce drug clearance.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Euphyllin retard N (Theophylline) overdose is defined by a spectrum of documented clinical manifestations that range from early signs of toxicity to severe, life-threatening events. Immediate emergency medical attention is required for any suspected overdose.


Documented Overdose Manifestations and Complications

Classification Manifestation or Outcome
Initial Signs of Toxicity Severe Nausea, repetitive Vomiting, Tremors, Restlessness, Irritability, and Tachycardia (rapid heart rate).
Life-Threatening Outcomes Severe Ventricular Arrhythmias, Seizures (Convulsions) or Status Epilepticus, and Cardiac Arrest.
Physiological Findings Hypokalemia (low potassium) and Hyperglycemia (high blood sugar).

Required Emergency Actions

Any individual experiencing these symptoms must seek emergency medical help immediately. Regulatory guidance mandates that no further doses of the medicine should be administered if signs of toxicity, such as severe vomiting or rapid heart rate, occur. The management framework is strictly supportive, as no specific antidote is known for Theophylline overdose. Procedures often involve continuous monitoring of vital signs, ECG, and serum Theophylline concentration, with interventions such as Activated Charcoal and, in severe cases, Extracorporeal Elimination (e.g., Hemodialysis) as documented in official prescribing information.

Certain groups, including elderly patients and those with existing conditions like Liver Disease, are officially noted to be at an increased risk for toxicity due to reduced drug clearance.

Advertisements

Therapeutic Uses of Euphyllin retard N

What Euphyllin Retard N Treats: Main Uses and Benefits

Euphyllin Retard N is an oral medication containing the bronchodilator theophylline. It is commonly used to help with conditions characterized by periods of heightened symptoms in chronic lung diseases, such as asthma, chronic bronchitis, and emphysema. The medication's role is primarily focused on supportive symptom management, relevant in contexts involving heightened systemic burden.

Theophylline is applied in addressing the manifestations of these chronic obstructive conditions. The bronchodilator action is applied in addressing the narrowing of the airways, which supports the patient during difficult episodes by easing distress. It contributes to easing the overall symptom load associated with chronic respiratory conditions.

The extended-release formulation assists with maintaining functional stability when symptoms become temporarily overwhelming. It helps ease the overall symptom burden associated with chronic respiratory conditions. The medication is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities.


Quick Fact: Focus on Symptoms related to physical discomfort (such as wheezing or breathlessness)


Regulatory References

  1. NIH MedlinePlus Drug Information on Theophylline
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Euphyllin retard N?

Euphyllin retard N (Theophylline) eligibility is strictly defined by regulatory bodies due to the medicine’s narrow therapeutic window, which necessitates precise control over drug levels in the body. The eligibility profile is structured around populations that carry an increased risk of drug accumulation or toxicity.

Absolute Contraindications

Use of this medicine is formally contraindicated in any individual with a known hypersensitivity or allergy to theophylline or any other xanthine derivative.

Populations Requiring Restricted or Conditional Use

Use is officially restricted and requires caution in populations where theophylline clearance is significantly impaired or unstable:

  • Age Restrictions: The medicine is restricted in infants (under 1 year of age) and elderly patients (over 60 years of age) due to highly variable or reduced drug clearance rates.
  • Organ Function & Illness: Caution is required for patients with liver disease (e.g., cirrhosis, acute hepatitis), congestive heart failure, sepsis, shock, or a sustained high fever. These conditions can drastically slow the body's ability to eliminate the drug.
  • Comorbidities: Conditional use applies to individuals with active peptic ulcer disease or a history of a seizure disorder.
  • Pregnancy Status: Use is restricted during the third trimester of pregnancy due to official documentation of altered drug handling that increases toxicity risk. Use during breastfeeding is generally allowed but requires caution.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Euphyllin retard N contains theophylline, which has an official interaction profile defined by its metabolism, clearance rate, and pharmacodynamic effects, based strictly on regulatory documents.

Official Interaction Statements

  • Clearance-Reducing Substances: Co-administration with enzyme inhibitors such as Enoxacin, Cimetidine, and certain Fluoroquinolones (e.g., Ciprofloxacin) significantly decreases the clearance of theophylline, resulting in a documented increase in systemic exposure.
  • Clearance-Increasing Substances: Co-administration with enzyme inducers such as Rifampin, Phenytoin, and Carbamazepine increases the clearance of theophylline, leading to a reduction in serum concentration.
  • Pharmacodynamic Synergy: Theophylline is documented to interact with the anesthetic Halothane, increasing the risk of ventricular arrhythmias due to synergistic effects. It also antagonizes the sedative effects of Benzodiazepines.
  • Contraindicated Combinations: Co-administration with Riociguat and Febuxostat is classified as a severe interaction risk due to significant effects on concentration or mechanism, and is often prohibited in official labeling.

Lifestyle and Special Population Considerations

Substance / Condition Documented Interaction Profile
Tobacco Smoke Induces hepatic enzymes, resulting in a 50% to 100% decrease in theophylline exposure, as stated in regulatory labeling.
Smoking Cessation Reverses enzyme induction, leading to an increase in serum concentrations and requiring re-evaluation of exposure.
Enteral (Tube) Feedings Interference with absorption requires the feeding to be interrupted for one hour before and one hour after the theophylline dose, as specified in regulatory documents.
Hepatic Impairment Clearance is reduced by 50% or more, increasing the risk of toxicity from any co-administered substance that affects metabolism.

These official statements structure the product's regulatory profile, establishing constraints for use based on documented pharmacokinetic modifications and pharmacodynamic effects with co-administered substances.

Advertisements

Mechanism of Action

The mechanism of action for Euphyllin retard N derives from its active ingredient, Theophylline, which acts through three distinct pathways to modulate respiratory function.

Influence on Smooth Muscle Tone by Enzyme Inhibition

Its primary action is the non-selective competitive inhibition of Phosphodiesterase (PDE) enzymes, particularly PDE3, within bronchial smooth muscle cells. This inhibition prevents the degradation of the cellular messenger cyclic AMP (cAMP), resulting in its elevated intracellular concentration. The subsequent cascade promotes the relaxation of muscles surrounding the air passages. This molecular action results in the physiological change of increased airway diameter.

Receptor Blockade and Influence on Airway Reactivity

Theophylline also functions as a non-selective antagonist at Adenosine Receptors (A1, A2A, A2B). By blocking these receptors, the drug influences the signaling of the natural mediator Adenosine, which would otherwise trigger the release of pro-constrictive chemicals. This antagonism influences the pathways governing airway responsiveness and limits non-specific constrictive signaling.

Regulation of Gene Expression Pathways in Chronic Inflammation

At the molecular level, the drug modulates genetic processes by indirectly enhancing the activity of the enzyme Histone Deacetylase-2 (HDAC2). This mechanism is crucial for removing acetyl groups from DNA-associated proteins, which helps to suppress the transcription of pro-inflammatory genes (e.g., those driven by NF-kappa B). This function serves as a mechanistic pathway for the regulation of chronic inflammatory processes in the airways.

Advertisements

Dosage and Administration Information

The administration of Euphyllin retard N (Theophylline prolonged-release) is governed by instructions that emphasize precise, individualized control of the drug level.

Administration and Dosing

Guideline Official Instruction
Route of Administration Oral (by mouth)
Dosing Schedule Highly individualized; determined by Therapeutic Drug Monitoring (TDM). The goal is to maintain theophylline serum concentrations, typically between 8-20 mug/mL, or in some contexts, 5-12 mug/mL.
Frequency and Timing The total daily dose is commonly divided into two individual doses, usually taken every 12 hours. Treatment may begin in the evening and is increased gradually over several days.
Administration Method Must be taken after meals with plenty of liquid. Prolonged-release capsules may be opened, and the contents (microgranules) swallowed unchewed. Prolonged-release tablets must be swallowed whole, not crushed or chewed.

Special Procedural Requirements

  • Mandatory Monitoring: Regular TDM is required to measure the serum theophylline concentration to guide dose adjustment, especially at initiation of therapy or when symptoms of potential toxicity or insufficient effect occur.
  • Dose Calculation: The dose must be calculated based on the patient's Normal Body Weight.
  • Population Adjustments: A lower dose and cautious titration are required for the elderly (60 years and over) and patients with impaired clearance (e.g., heart failure, liver dysfunction). Higher doses per kilogram of body weight may be required for smokers due to increased clearance.
  • Restriction: Prolonged-release preparations are not indicated for the acute treatment of severe bronchospasm or status asthmaticus.

These instructions structure the use of the medicine as a continuous therapy that requires a fixed schedule and mandatory laboratory monitoring to ensure proper administration and maintenance of the target drug concentration. The duration of use is determined solely by the treating physician.

Advertisements

Recent Clinical Evidence

Euphyllin retard N: Overview of Clinical Studies

This section summarizes the structure of clinical research conducted on the sustained-release Theophylline formulation. Findings describe group patterns observed in the studies and help contextualize how patients reported their experience, but research does not determine whether an individual will respond similarly.


Evidence for Use in Chronic Obstructive Pulmonary Disease (COPD)

Research includes Randomized Controlled Trials (RCTs) and Systematic Reviews focused on adults with stable COPD. These studies often examined the effect of the medicine when participants were already receiving other treatments. Studies monitored changes in key measures of lung function, which is a physiological measurement of air flow. Reports describe measured changes in these physiological markers compared to non-active control groups. However, findings were mixed regarding a consistent reduction in the rate of severe flare-ups (outcomes describing episodic or acute changes) in these research settings.


Evidence for Use in Chronic Asthma (Maintenance Therapy)

The evidence for chronic asthma management also includes RCTs. These studies primarily focused on measuring outcomes monitoring physiological strain or stress and the patient’s need for rescue medication. Studies explored how symptoms evolved in the observed populations, and data show patterns related to lung function markers when compared to placebo groups. Comparative research was studied for how outcomes from this drug compare with findings from other established maintenance therapies.


Evidence in Specific Patient Groups and Research Gaps

Research has monitored the medicine's use in children and adolescents with chronic asthma, though findings for these subgroups are uncertain due to variability. Follow-up durations in many key trials were limited, meaning long-term effects are not fully established. Comparative evidence is lacking against many of the newest inhaled and oral treatments used for asthma and COPD today, and research findings on its position against newer options often relies on indirect comparisons.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Euphyllin retard N (FAQ)

Q: What is the main ingredient in Euphyllin retard N?

The main ingredient in Euphyllin retard N is theophylline, which belongs to a class of medicines called methylxanthines.

Q: What is Euphyllin retard N used for?

Euphyllin retard N is used to prevent and treat shortness of breath in patients with chronic obstructive airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD). It helps to relax the muscles in the airways and reduce their sensitivity to stimuli.

Q: How does theophylline work?

Theophylline works primarily by relaxing the smooth muscles in the lungs' airways (bronchi) and blood vessels. This effect helps to widen the airways, making it easier to breathe. It may also have anti-inflammatory effects and can stimulate the respiratory drive.

Q: What is the meaning of 'retard' in the name Euphyllin retard N?

The term 'retard' indicates that the medicine is a sustained-release or prolonged-release formulation. This means the active ingredient, theophylline, is released slowly over a longer period. This allows for less frequent dosing and helps maintain a more stable level of the medicine in the blood.

Q: Can Euphyllin retard N be taken with food?

Generally, Euphyllin retard N prolonged-release tablets should be taken with a meal or immediately after a meal. This can help to minimize the risk of gastrointestinal side effects. The tablets must be swallowed whole with plenty of liquid and should not be chewed or crushed.

Q: Is Euphyllin retard N the same as aminophylline?

No, Euphyllin retard N (theophylline) is not the same as aminophylline, although they are closely related. Aminophylline is a salt of theophylline and contains about 79% theophylline by weight. Aminophylline is often used in intravenous forms for urgent treatment, while theophylline is the active ingredient in the prolonged-release tablets like Euphyllin retard N.

Q: How should Euphyllin retard N be stored?

Euphyllin retard N should be stored in its original packaging to protect it from moisture. It should be kept at room temperature, and away from the reach of children.

Advertisements

How should Euphyllin retard N be stored and disposed of?

How to Store and Dispose of Euphyllin retard N?

This medication's storage and disposal must strictly adhere to regulatory guidelines to maintain stability and ensure safety.


Storage Requirements

Theophylline sustained-release tablets must be kept at room temperature, protected away from excess heat and moisture. It is required that the product remain in its original container, which must be tightly closed. Storage is prohibited in environments like the bathroom due to heat and moisture. Child safety is mandatory: the medicine must be secured out of the sight and reach of children, and safety caps must always be locked.


Disposal Instructions

The safest method for discarding unused or expired tablets is through an official drug take-back location or program. If a take-back option is unavailable, the product must be mixed with an undesirable substance (such as dirt or used coffee grounds), sealed in a container, and placed in the trash. The tablets must not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Euphyllin retard N found in:

A-Z Index: